market-trends is the sole category represented across all 1 tracked stories. Adam Alanoff is most often covered alongside Agilent, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 4.7 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Adam Alanoff
market-trends is the sole category represented across all 1 tracked stories. Adam Alanoff is most often covered alongside Agilent, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 4.7 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.6 for that window. We currently track 1 Healthcare story that mention Adam Alanoff, all published on February 26, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Adam Alanoff. Shared-story counts are live from our verified record — not editorial picks.
Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue.
